179 related articles for article (PubMed ID: 15239334)
41. [Cyclooxygenase 2 and carcinogenesis].
Rodrigues S; Bruyneel E; Rodrigue CM; Shahin E; Gespach C
Bull Cancer; 2004 May; 91 Suppl 2():S61-76. PubMed ID: 15899629
[TBL] [Abstract][Full Text] [Related]
42. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Sanborn R; Blanke CD
Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
[TBL] [Abstract][Full Text] [Related]
43. Differential effect of cyclooxygenase-2 preferring [correction of prefering] inhibitors on electrically- and chemically-induced seizures in mice.
Reeta Kh; Mediratta PK; Mahajan P; Sharma KK
Indian J Physiol Pharmacol; 2003 Oct; 47(4):471-5. PubMed ID: 15266962
[No Abstract] [Full Text] [Related]
44. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
45. Cyclooxygenase-2 inhibitors: will they help us prevent diabetic nephropathy?
Zatz R; Fujihara CK
Kidney Int; 2002 Sep; 62(3):1091-2. PubMed ID: 12164896
[No Abstract] [Full Text] [Related]
46. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer.
Pruthi RS; Derksen E; Gaston K; Wallen EM
Urology; 2004 Oct; 64(4):637-42. PubMed ID: 15491687
[No Abstract] [Full Text] [Related]
47. [Assessing the coxibs].
Paakkari I
Duodecim; 2003; 119(21):2071-7. PubMed ID: 14655538
[No Abstract] [Full Text] [Related]
48. [Cylooxgenase-2: a novel molecular target for the prevention and treatment of head and neck cancer on the advance of basic and preclinical research].
Guo W; Zeng QH; Wang CY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 May; 39(3):261-3. PubMed ID: 15196405
[No Abstract] [Full Text] [Related]
49. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Lamarque D
Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
[TBL] [Abstract][Full Text] [Related]
50. The potential danger of COX-2 inhibitors.
Norman RJ; Wu R
Fertil Steril; 2004 Mar; 81(3):493-4. PubMed ID: 15037388
[TBL] [Abstract][Full Text] [Related]
51. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
52. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
53. Proceedings of the RTOG (Radiation Therapy Oncology Group) Symposium: COX-2 Inhibitors and Cancer Therapeutics. June 2001.
Am J Clin Oncol; 2003 Aug; 26(4):S45-125. PubMed ID: 12902854
[No Abstract] [Full Text] [Related]
54. Rapid method for identification of chemopreventive compounds using multiplex RT-PCR for cyclooxygenase mRNA expression.
Malik M; Magnuson BA
Cancer Detect Prev; 2004; 28(4):277-82. PubMed ID: 15350631
[TBL] [Abstract][Full Text] [Related]
55. Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials.
Blanke CD; Masferrer JL
Prog Exp Tumor Res; 2003; 37():243-60. PubMed ID: 12795058
[No Abstract] [Full Text] [Related]
56. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Hedner T; Himmelmann A
Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
[No Abstract] [Full Text] [Related]
57. Pain from myelofibrosis treated with regular pamidronate.
Perkins P; Curtin NJ; Green AR; Booth S
Br J Haematol; 2004 Nov; 127(3):366-7. PubMed ID: 15491303
[No Abstract] [Full Text] [Related]
58. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
[TBL] [Abstract][Full Text] [Related]
59. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
Nam KT; Hahm KB; Oh SY; Yeo M; Han SU; Ahn B; Kim YB; Kang JS; Jang DD; Yang KH; Kim DY
Clin Cancer Res; 2004 Dec; 10(23):8105-13. PubMed ID: 15585646
[TBL] [Abstract][Full Text] [Related]
60. Constituents of the seeds of Hernandia ovigera with inhibitory activity against cyclooxygenase-2.
Jang DS; Cuendet M; Su BN; Totura S; Riswan S; Fong HH; Pezzuto JM; Kinghorn AD
Planta Med; 2004 Oct; 70(10):893-6. PubMed ID: 15490314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
